Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?
Speaker
Prof. dr. Leonard van den Berg
Neurologist
Prof. dr. Leonard van den Berg is a neurologist at University Medical Centre (UMC) Utrecht and ALS Centrum. He is experienced in conducting global ALS trials, established the prominent TRICALS site network, and is chair of the European Network for the Cure of ALS.
During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requirement of the EMA and FDA and statistical considerations.
They touched upon:
- Primary endpoints in ALS clinical trials
- Regulatory requirements: differences between EMA and FDA
- Statistical considerations for ALSFRS-R, survival and composites
Followed by a Q&A session.
Speakers: Prof. Leonard van den Berg, MD, PhD & Dr. Ruben van Eijk, MD, PhD
Related webinars
Webinar – Time to event trial designs in ALS: How useful are they?
LIVE WEBINAR | NOVEMBER 26 - 2024 | 17.00 CET Time to event trial designs in ALS: How useful are they? During the webinar hosted by Lieza Exalto, Ruben van Eijk, Lotte Smets and Jordi van Unnik will touch upon:An introduction to event-driv...
Webinar – Clinical consequences of the New MASLD Nomenclature
On the 27th of June, we organized the webinar: 'Clinical Consequences of the New MASLD Nomenclature' with guest speaker Prof. Maja Thiele.During this webinar, our speaker and hosts dived into the following topics:Is the MASLD nomeclature...
Webinar: Plasma biomarkers for diagnosis and monitoring of neurodegenerative disorders
On October 15, at 16.00 CEST, we presented the webinar:Plasma biomarkers for diagnosis and monitoring of neurodegenerative disordersTopics that are discussed:Plasma biomarkers, such as Amyloid, pTau and NfL. Treatment effect in ne...